Biovitrum has Successfully Completed the First Phase I Trial of its 5-HT6 Receptor Antagonist (BVT.74316)


A clinical phase I trial of BVT.74316 has now been successfully completed. This first clinical study, with the objective to test safety and tolerability in escalating single-dose and repeated-dose administration was started in August 2006. In total, 98 healthy volunteers have participated in the study. A safe and tolerable dose has been identified.

"This project does not fall within the new business focus of Biovitrum since part of our strategy is to out-license primary care indication projects. It is therefore natural that we do not continue to drive the development of this program further," says Biovitrum's CEO Martin Nicklasson. "Instead we work on re-focusing our research and other activities to the development of specialist care drugs, directed towards small patient groups with large unmet medical needs. In this area we already have a strong portfolio with four projects in clinical phase I and II and products that we sell in the Nordic countries. Now, having reached this milestone the project will be offered for out-licensing," Martin Nicklasson concludes.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances